EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan

Yuan-Hung Wu iD, Yu-Mei Kang, Yu-Wen Hu, Keng-Li Lan, Sang-Hue Yen, Tzu-Yu Lai, Tien-Li Lan, Yuh-Min Chen, Chao-Hua Chiu, Yung-Hung Luo, Heng-Sheng Chao, Chi-Lu Chiang und 9 weitere

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yuan-Hung Wu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population.

Methods

To evaluate the effects of old age and EGFR mutation on treatment outcomes and toxicity, we reviewed the medical records of 71 consecutive patients with inoperable early‐stage non‐small cell lung cancer (NSCLC) who received SABR at Taipei Veterans General Hospital between 2015 and 2021.

Results

The study revealed that median age, follow‐up, Charlson comorbidity index, and ECOG score were 80 years, 2.48 years, 3, and 1, respectively. Of these patients, 37 (52.1%) were 80 years or older, and 50 (70.4%) and 21 (29.6%) had T1 and T2 diseases, respectively. EGFR mutation status was available for 33 (46.5%) patients, of whom 16 (51.5%) had a mutation. The overall survival rates at 1, 3, and 5 years were 97.2, 74.9, and 58.3%, respectively. The local control rate at 1, 3, and 5 years was 97.1, 92.5, and 92.5%, respectively. Using Cox proportional hazards regression we found that male sex was a risk factor for overall survival ( p = 0.036, 95% CI: 1.118–26.188). Two patients had grade 2 pneumonitis, but no other grade 2 or higher toxicity was observed. We did not find any significant differences in treatment outcomes or toxicity between patients aged 80 or older and those with EGFR mutations in this cohort.

Conclusion

These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early‐stage NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgerySmall Cell Lung CarcinomaAgedAged, 80 and overHumansMaleErbB ReceptorsNeoplasm StagingTaiwanTreatment Outcome

Stichwörter der Autor:innen

EGFRSABRlung cancerold age

Substanzen

EGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
  • Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
  • Institute of Traditional Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
  • Department of Radiation Oncology, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan.
  • Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

ORCID-Profile: Yuan-Hung Wu, Chien-Sheng Huang

Zitieren

APA

Wu, Y. H., Kang, Y. M., Hu, Y. W., Lan, K. L., Yen, S. H., Lai, T. Y., Lan, T. L., Chen, Y. M., Chiu, C. H., Luo, Y. H., Chao, H. S., Chiang, C. L., Shiao, T. H., Yang, C. N., Hsu, W. H., Wu, Y. C., Hsu, H. S., Hung, J. J., Huang, C. S., …, & Chen, Y. W. (2023). Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14786

Vancouver

Wu YH, Kang YM, Hu YW, Lan KL, Yen SH, Lai TY, et al. Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14786

BibTeX
@article{Wu2023,
  author = {Wu, Yuan-Hung and Kang, Yu-Mei and Hu, Yu-Wen and Lan, Keng-Li and Yen, Sang-Hue and Lai, Tzu-Yu and Lan, Tien-Li and Chen, Yuh-Min and Chiu, Chao-Hua and Luo, Yung-Hung and Chao, Heng-Sheng and Chiang, Chi-Lu and Shiao, Tsu-Hui and Yang, Chao-Neng and Hsu, Wen-Hu and Wu, Yu-Chung and Hsu, Han-Shui and Hung, Jung-Jyh and Huang, Chien-Sheng and Hsu, Po-Kuei and Chen, Yi-Wei},
  title = {Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14786}
}
Kostenlos starten →